中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
10期
1254-1256
,共3页
转移性结直肠癌%伊立替康%对症支持治疗
轉移性結直腸癌%伊立替康%對癥支持治療
전이성결직장암%이립체강%대증지지치료
Advanced metastatic colorectal cancer%Irinotecan%Suitable-symptom nutritional support
目的 评价伊立替康联合对症支持疗法在不能耐受联合化疗的转移性结直肠癌患者治疗中的临床疗效及不良反应.方法 选取我院原发肿瘤、淋巴结及远处转移(TNM)分期均为Ⅳ期的结直肠癌患者共24例,卡氏行为状态评分为40～ 60分,完全随机将患者分为观察组(13例)和对照组(11例).观察组患者第1、8天给予伊立替康125 mg/m2静脉滴注,30 ～ 90 min内滴完,联合对症支持治疗；对照组患者单纯给予对症支持治疗.观察2组患者临床疗效和不良反应发生情况.结果 观察组治疗有效率为15.4％(2/13),疾病控制率53.8％(7/13)；对照组治疗有效率为0,疾病控制率为8.2％(2/11).治疗1年后随访,观察组患者的生存率高于对照组[53.8％(7/13)比27.3％(3/11),P＜0.05].治疗后,观察组生存质量提高患者的比率高于对照组,差异有统计学意义[53.8％(7/13)比27.3％(3/11),P＜0.05].化疗的不良反应大多数患者可耐受,并未因此中断治疗.结论 与单纯给予对症支持治疗相比,伊立替康联合支持治疗可以改善不能耐受联合化疗的转移性结直肠癌患者的疾病控制率,提高患者生存率和生活质量,且患者耐受性和依从性好.
目的 評價伊立替康聯閤對癥支持療法在不能耐受聯閤化療的轉移性結直腸癌患者治療中的臨床療效及不良反應.方法 選取我院原髮腫瘤、淋巴結及遠處轉移(TNM)分期均為Ⅳ期的結直腸癌患者共24例,卡氏行為狀態評分為40～ 60分,完全隨機將患者分為觀察組(13例)和對照組(11例).觀察組患者第1、8天給予伊立替康125 mg/m2靜脈滴註,30 ～ 90 min內滴完,聯閤對癥支持治療；對照組患者單純給予對癥支持治療.觀察2組患者臨床療效和不良反應髮生情況.結果 觀察組治療有效率為15.4％(2/13),疾病控製率53.8％(7/13)；對照組治療有效率為0,疾病控製率為8.2％(2/11).治療1年後隨訪,觀察組患者的生存率高于對照組[53.8％(7/13)比27.3％(3/11),P＜0.05].治療後,觀察組生存質量提高患者的比率高于對照組,差異有統計學意義[53.8％(7/13)比27.3％(3/11),P＜0.05].化療的不良反應大多數患者可耐受,併未因此中斷治療.結論 與單純給予對癥支持治療相比,伊立替康聯閤支持治療可以改善不能耐受聯閤化療的轉移性結直腸癌患者的疾病控製率,提高患者生存率和生活質量,且患者耐受性和依從性好.
목적 평개이립체강연합대증지지요법재불능내수연합화료적전이성결직장암환자치료중적림상료효급불량반응.방법 선취아원원발종류、림파결급원처전이(TNM)분기균위Ⅳ기적결직장암환자공24례,잡씨행위상태평분위40～ 60분,완전수궤장환자분위관찰조(13례)화대조조(11례).관찰조환자제1、8천급여이립체강125 mg/m2정맥적주,30 ～ 90 min내적완,연합대증지지치료；대조조환자단순급여대증지지치료.관찰2조환자림상료효화불량반응발생정황.결과 관찰조치료유효솔위15.4％(2/13),질병공제솔53.8％(7/13)；대조조치료유효솔위0,질병공제솔위8.2％(2/11).치료1년후수방,관찰조환자적생존솔고우대조조[53.8％(7/13)비27.3％(3/11),P＜0.05].치료후,관찰조생존질량제고환자적비솔고우대조조,차이유통계학의의[53.8％(7/13)비27.3％(3/11),P＜0.05].화료적불량반응대다수환자가내수,병미인차중단치료.결론 여단순급여대증지지치료상비,이립체강연합지지치료가이개선불능내수연합화료적전이성결직장암환자적질병공제솔,제고환자생존솔화생활질량,차환자내수성화의종성호.
Objective To evaluate the clinical efficacy and the toxicity of irinotecan combined with suitable-symptom nutritional supporting treatment for patients with advanced metastatic colorectal cancer who were intolerant of chemotherapy.Methods Twenty-four patients with tumor node metastases(TNM)stage Ⅳ advanced metastatic colorectal cancer were enrolled,and their Karnofsky performance status(KPS)score was 40-60.The observation group had 13 cases and the control group was 11 cases.The observation group was treated by irinotecan and suitable-symptom nutritional support; the control group was treated by suitable-symptom nutritional support.Results Tumor response rate of patients was 15.4％(2/13)in the observation group; the disease control rate was 53.8％(7/13).Survival rate of 1-year in the observation group was higher than that in the control group [53.8(7/13)vs 27.3(3/11),P ＜ 0.05]; KPS increasing rate was higher than that of the control group [53.8(7/13)vs 27.3(3/11),P ＜ 0.05].Adverse chemotherapy reaction was tolerable.Conclusions Disease control rate and 1-year survival rate in the observation group are significantly higher than those in the control group in advanced metastatic colorectal cancer.It can improve life quality.Patient tolerance and compliance are satisfactory.
